WESTMINSTER, Colo., June 13 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH - News) announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $100 million of its common stock, preferred stock, depository shares, debt securities and/or warrants, either individually or in units, in one or more offerings. As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement and the Company is not required to offer the securities in the future pursuant to the registration statement. The terms of any offering under the registration statement will be established at the time of the offering. Proceeds from the sale of any securities will be used for the purposes described in a prospectus supplement filed at the time of an offering. If and when the SEC declares this registration statement effective, the Company intends to retire the unused portion of its previous shelf registration statement that was declared effective by the SEC in 2004.
